Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 106

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 106
---
 expenses

Finance expenses increased
by approximately $2,159 thousand, or 5,140.0%, to approximately $2,201 thousand for the year ended December 31, 2023, compared to approximately
$42 thousand for the year ended December 31, 2022. The increase resulted mainly from a fair value revaluation of convertible notes.

Net loss

Net loss increased by approximately
$2,683 thousand to approximately $4,132 thousand for the year ended December 31, 2023, compared to $1,449 thousand for the year ended
December 31, 2022. The increase was mainly the result of an increase in our general and administrative expenses and finance expenses,
net.

Critical Accounting Policies

We describe our significant
accounting policies and estimates in Note 2 to our annual financial statements contained elsewhere in this prospectus. We believe
that these accounting policies and estimates are critical in order to fully understand and evaluate our financial condition and results
of operations.

We prepare our financial statements
in accordance with U.S. GAAP.

In preparing these financial
statements, management has made judgments, estimates and assumptions that affect the application of our accounting policies and the reported
amounts recognized in the financial statements. On a periodic basis, we evaluate our estimates, including those related to share-based
compensation and derivatives. We base our estimates on historical experience, authoritative pronouncements and various other assumptions
that we believe to be reasonable under the circumstances. Actual results may differ from these estimates.

Recently-Issued Accounting Pronouncements

Certain recently-issued accounting
pronouncements are discussed in Note 2, Significant Accounting Policies, to the financial statements included in elsewhere in this
registration statement, regarding the impact of the U.S. GAAP standards as issued by the Financial Accounting Standards Board that we
will adopt in future periods in our financial statements.

<div align='center'>65</div>

Emerging Growth Company Status

We qualify as an “emerging
growth company” as defined in the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other
burdens that are otherwise applicable generally to public companies. These provisions include:

| ● | a requirement to present only two years of audited financial statements in addition to any required interim financial statements and correspondingly reduced Management’s Discussion and Analysis of Financial Condition and Results of Operations disclosure; |

| ● | to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding